On October 26-28, 2022, the 19th China Association of Clinical Laboratory Practice Expo (short for "CACLP") was held in Nanchang Greenland International Expo Center. As the flagship exposition of IVD industry and an important wind vane of industry development, this CACLP Expo attracted more than 1,400 enterprises and many industry insiders. As one of the leading enterprises in the field of pathological diagnosis in China, LBP has made a brilliant appearance with its overall solutions for pathology.
Overall solutions for pathology improve the work efficiency of pathology departments
LBP has been deeply engaged in the pathological diagnosis for many years, and is committed to achieving standardization, automation, digitalization and intelligence (hereinafter referred to as "four aspects") in the field of pathology to help pathology departments improve diagnostic quality and overall efficiency. This exhibition presented series of products and devices including early tumor screening, precise tumor diagnosis, companion diagnostics, digital pathology, conventional pathology, etc., which attracted many professional visitors to stop by and learn about:
01 "Reagent + equipment + scanner +AI" digital and intelligent pathology solutions
Liquid-based cytology, as the first product line to implement the concept of "four aspects", has the following features: fully automated staining equipment with high throughput and supporting standardized reagents to ensure high quality sectioning results; fully automated digital section scanning system, with an average scanning time of about 2 min for 7 layers, a non-sticking design that allows overnight scanning, and dual-channel design to enable cyclic loading, which is more in line with the work habits of pathology departments; the pathological medical image analysis and processing system developed in exclusive cooperation with Tencent AI LAB, with a 75%-90% negative exclusion rate, allowing pathologists to diagnose more accurately and calmly. From the automation of sectioning and staining, standardization of sample processing, digitization of pathological sections, and intelligence of reading and diagnosis, it realizes the innovative work mode of cytopathology and improves the working efficiency and environment of pathologists.
02 Cervical cancer screening cytology + HPV test scheme
Combined liquid-based cytology LBP and HPV genetic testing is the authoritative cervical cancer screening recommended by the latest Cervical Cancer Diagnosis and Treatment Guidelines. LBP is one of the few companies in China with the above two series of products, which form a significant synergy effect. The fully automated, high-throughput nucleic acid hybridization oven exhibited at the exhibition significantly shortens nucleic acid hybridization test time, saves labor and achieves technical quality control. Combined with liquid-based cytology products, it can realize the integrated solution of single sampling and two tests.
03 Tumor diagnosis, covering molecular and protein technology platform products
The Company has three major technology platforms: cytology, immunology and molecular, forming precision tumor diagnosis products covering dozens of cancer types such as cervical cancer, breast cancer, lung cancer, lymphoma, leukemia and soft tissue tumors. Among them, nearly 400 kinds of FISH probes have been developed independently, which not only meets the clinical diagnostic needs, but also helps departments improve their scientific research, and more than 70 articles have been published using LBP's probes. Meanwhile, the automatic FISH pre-processing system enables automation and standardization of the FISH detection, which greatly improves the working efficiency. The Company's independently developed more than 200 commonly used antibodies for the IHC product line have been verified by multiple platforms for quality and compatibility, and are complete with the automatic IHC equipment to meet the clinical needs with multiple throughput options.
04 From IHC precision diagnosis to drug companion diagnostics
LBP owns fully independent intellectual property rights of recombinant antibody development technology, which enables IHC detection antibodies to be customized for tumor-targeted drugs, providing full-chain services and one-stop solutions for pharmaceutical companies in companion diagnostics through combining advantageous resources.
In addition, the products of the conventional pathology product line were also displayed, from sample taking and numbering to dehydration and embedding and to section staining, covering the equipment required for the whole process of routine tissue processing in the pathology departments. Matrix-type integrated services enable rapid response and perception of every customer need, making diagnosis more accurate, reliable, efficient and convenient!
Pathological capacity enhancement scheme, providing diversified pathology service business
LBP actively responds to the national call to help primary hospitals to improve their pathology capacity, and provides schemes to improve the capacity of primary pathology departments, develop regional pathology diagnosis centers, develop regional intelligent screening centers of cervical cancer, etc., so that each primary hospital has its own pathology department, jointly realizing medical care, diagnosis and treatment in the hospital!
With the vision of "benefiting society with precision medical diagnosis", LBP keeps investing in R&D and developing new products to create the conditions for medical institutions at all levels to apply technologies that are in sync with the world, so that patients reduce their pain and burden and get better opportunities to live.
